



Hospitalizations and emergency attendance averted by influenza vaccination in Victoria, Australia, 2017 – 2019

Original Paper

Cite this article: Pendrey CGA, Khvorov A, Nghiem S, Rahaman MR, Strachan J and Sullivan SG (2024). Hospitalizations and emergency attendance averted by influenza vaccination in Victoria, Australia, 2017 – 2019. *Epidemiology and Infection*, **152**, e111, 1–10 <https://doi.org/10.1017/S0950268824001122>

Received: 28 December 2023

Revised: 05 June 2024


Accepted: 23 August 2024

Keywords:

epidemiology; influenza; prevention; vaccination (immunization); vaccine policy development

Corresponding author:

Catherine G. A. Pendrey;
Email: catherine.pendrey@anu.edu.au

Catherine G. A. Pendrey^{1,2,3} , Arseniy Khvorov^{2,4}, Son Nghiem⁵, Md R. Rahaman¹, Janet Strachan³ and Sheena G Sullivan^{2,4,6}

¹National Centre for Epidemiology and Population Health, The Australian National University, Canberra, ACT, Australia; ²WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; ³Communicable Diseases, Health Protection Branch, Department of Health, Melbourne, VIC, Australia; ⁴Department of Infectious Diseases, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; ⁵College of Health and Medicine, Australian National University, Canberra, ACT, Australia and ⁶Department of Epidemiology, University of California, Los Angeles, CA, USA

Abstract

Seasonal influenza epidemics result in high levels of healthcare utilization. Vaccination is an effective strategy to reduce the influenza-related burden of disease. However, reporting vaccine effectiveness does not convey the population impacts of influenza vaccination. We aimed to calculate the burden of influenza-related hospitalizations and emergency department (ED) attendance averted by influenza vaccination in Victoria, Australia, from 2017 to 2019, and associated economic savings. We applied a compartmental model to hospitalizations and ED attendances with influenza-specific, and pneumonia and influenza (P&I) with the International Classification of Diseases, 10th Revision, Australian Modification (ICD-10-AM) diagnostic codes of J09-J11 and J09-J18, respectively. We estimated an annual average of 7657 (120 per 100000 population) hospitalizations and 20560 (322 per 100000 population) ED attendances over the study period, associated with A\$85 million hospital expenditure. We estimated that influenza vaccination averted an annual average of 1182 [range: 556 – 2277] hospitalizations and 3286 [range: 1554 – 6257] ED attendances and reduced the demand for healthcare services at the influenza season peak. This equated to approximately A13 [range: A6 – A25] million of savings over the study period. Calculating the burden averted is feasible in Australia and a useful approach to demonstrate the health and economic benefits of influenza vaccination.

Introduction

Influenza is a major cause of morbidity, mortality, and health service utilization around the world [1–3]. Outbreaks and seasonal epidemics result in peaks that place significant strain on acute care services [3, 4] and economic expenditure [1, 5], especially in severe seasons. In Australia, seasonal influenza has been estimated to account for an annual average of 20702 hospitalizations [3]. From 2010 to 2014, Australia’s most populous state, New South Wales (NSW), recorded an average of 22619 influenza-related ED attendances [6].

Vaccination is an effective strategy to reduce the population burden of influenza [2, 7, 8]. The Australian Government provides free influenza vaccination to individuals aged ≥6 months who are at increased risk of severe influenza-related illness, under the National Immunization Program. In 2017, this included adults aged ≥65 years, pregnant women, individuals with specified medical conditions, and Aboriginal and Torres Strait Islander individuals aged <5 years and ≥15 years [9]. This scheme was subsequently expanded to provide adjuvanted and high-dose influenza vaccines for adults aged ≥65 years from 2018, and to include Aboriginal and Torres Strait Islander individuals of any age from 2019. In 2018, the Victorian Government commenced subsidizing vaccination for all children aged 6 months to 5 years [9]. Vaccination is provided free to hospital and aged care workers, and some health and community services and employers also provide free vaccinations for individuals ineligible for subsidized vaccination under these programmes. Anyone can purchase influenza vaccination privately at their own expense [10].

Vaccine effectiveness (VE) compares the rate of outcomes among vaccinated and unvaccinated populations [11]. The effectiveness of influenza vaccination varies each year depending on the antigenic similarity between the vaccine and circulating viruses, as well as the level of influenza transmission and virulence, vaccination coverage, timing of vaccination in relation to the commencement of seasonal transmission, and population susceptibility, age distribution and health status [2, 7, 12]. The dynamic nature of seasonal influenza and the many factors influencing VE mean that it can be challenging to interpret the overall impact of influenza

© The Author(s), 2024. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (<http://creativecommons.org/licenses/by-nc-sa/4.0>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use.



vaccination based on VE alone. For example, influenza vaccination with modest VE may still result in substantial population benefits, especially during severe seasons and seasons with high population coverage [8, 13].

To overcome this issue, the US CDC has developed the influenza burden averted method to more effectively communicate the impact of influenza vaccination on population health [8]. This method uses surveillance data for coverage, VE, and influenza-related outcomes to model the additional burden of disease that would have been expected to occur in the absence of influenza vaccination [8, 12, 13]. This methodology has been applied in various countries around the world [2, 8, 12, 14], but not yet in Australia. In 2018, Tokars *et al.* undertook an update and revalidation of this model and developed a revised method with improved accuracy [12].

In this study, we applied this updated model to calculate the burden of hospitalizations and ED attendances averted by influenza vaccination in Victoria, Australia. We estimated the economic costs associated with influenza-related hospitalizations and ED attendances and the savings associated with the burden averted. We focused on the pre-pandemic period, as COVID-19-related restrictions resulted in major disruptions to influenza transmission from 2020 [15].

Methods

We utilized the methods described by Tokars *et al.* [12] to estimate the hospitalizations averted by influenza vaccination in Victoria, the second most populous state of Australia, from 1 January 2017 to 31 December 2019 [16], and additionally applied this approach to estimate the number of ED attendances averted. In this model, monthly counts of vaccinations administered in each age group, seasonal VE, and age-group-specific monthly hospitalization and ED attendance counts were used to derive the number of events that would be expected to occur in the absence of vaccination (Supplementary Figure S1). The difference between the number of events expected in the absence of vaccination and the actual

number observed was calculated to derive the burden averted by influenza vaccination [12]. All statistical analyses were conducted in R version 4.1.2. Model inputs are summarized in Table 1.

Data sources

Hospitalization data were obtained from the Victorian Admitted Episodes Dataset (VAED) between 1 January 2017 and 31 December 2019 [17]. VAED includes demographic, administrative, and clinical data for all admitted patients to public and private hospitals in Victoria. One principal and up to 39 additional diagnostic codes are recorded using the ICD-10-AM coding system [17]. Following the methods of Nazareno *et al.* [3], we excluded hospitalizations where the care type was classified as elective (planned and routine) or post-mortem for organ donation. Statistical hospitalizations were included as these represent the commencement of a distinct new episode of care [17].

ED attendance data were obtained from the Victorian Emergency Minimum Dataset (VEMD) between 1 January 2017 and 31 December 2019 [18]. VEMD provides demographic, administrative, and clinical data for individuals attending public and private EDs within Victoria. One principal and up to two additional diagnoses are recorded using ICD-10-AM codes. Reporting diagnoses is optional for private hospitals [18]; however, in Australia, 96% of emergency department (ED) care is provided in public hospitals [19].

For both VAED (hospitalizations) and VEMD (ED attendance), influenza-related events were defined as hospitalizations or ED attendances where an influenza-related diagnostic code was recorded in any diagnostic field. Two well-established case definitions for influenza-related events were evaluated. The first was defined by events with an influenza-specific ICD-10-AM code (J09-J11), and the second by events with a pneumonia and/or influenza (P&I) (J09-J18) diagnostic code [3, 20].

Population data for Victoria were accessed using publicly available data from the Australian Bureau of Statistics [16]. Mid-year quarterly estimates were used as estimates of the annual population

Table 1. Model inputs: population, vaccine coverage and vaccine effectiveness, Victoria, 2017–2019

	2017		2018		2019	
Population by age group in years	<i>n</i>		<i>n</i>		<i>n</i>	
0.5–4	445074		446430		444215	
5–14	747737		765140		783244	
15–49	3097809		3159304		3212667	
50–64	1075884		1087984		1104236	
65+	894248		920380		947732	
All ages	6260752		6379238		6492094	
Vaccine effectiveness ^a	%	95% CI	%	95% CI	%	95% CI
All ages	15	(0–32)	56	(44–65)	43	(36–49)
Vaccine coverage ^b	%	95% CI	%	95% CI	%	95% CI
Start of season	27	(16–40)	39	(27–51)	47	(40–54)
End of season	48	(33–63)	44	(26–64)	64	(46–80)

^a2017 VE lower 95% CI estimate was -6%, (11) and was therefore assumed to be 0%. (23)

^bSmoothed vaccine coverage, start and end of season population estimates (all ages).

Data sources: Australian Bureau of Statistics (16), Influenza Complications Alert Network (11, 21, 22), Victorian Sentinel Practices Influenza Network (Supplementary Figure S1).

for each age group. As age is recorded as whole numbers within this dataset, half of those with age recorded as 0 years were removed to account for those aged <6 months who are ineligible for influenza vaccination.

VE estimates were obtained from the Influenza Complications Alert Network, a hospital-based sentinel surveillance network. These VE estimates were calculated using test-negative studies for individuals admitted to sentinel hospitals within Australia during each influenza season within the study period. To calculate VE, vaccination rates were compared between cases, hospitalized individuals who tested positive for influenza via nucleic acid detection, and controls, frequency-matched hospitalized individuals with acute respiratory infections who tested negative for influenza [11, 21, 22]. In contrast to case identification in this study, which relied on ICD-10-AM codes, this process relied on active case finding [23]. All-age estimates of VE were used, as age group-specific estimates were of low precision in most instances. Low and high VE estimates were obtained from 95% confidence limits. Confidence intervals (CI) with a lower bound <0% were truncated to 0% [24].

Monthly estimates of the proportion of the population vaccinated against influenza within each influenza season were obtained from the Victorian Sentinel Practices Influenza Network (VicSPIN), a collection of primary care clinics participating in sentinel influenza surveillance [25]. The number of attendees presenting with influenza-like illness who tested negative for influenza was used to calculate monthly estimates of the proportion of the population that was vaccinated, with 95% CI. The number of attendees was insufficient to calculate age-group-specific coverage estimates. Estimates were smoothed to account for fluctuations in monthly estimates generated by variations in sampling by performing ordinary least squares linear regression of the monthly proportion of vaccinated individuals within the sample against the log of the month within each year of the study (Supplementary Figure S2). Proportions were multiplied by population to estimate monthly counts of vaccinated individuals in each age group.

Compartmental model of averted hospitalizations and ED attendance

The compartmental model of seasonal influenza transmission used to derive the number of events that would be expected to occur in the absence of vaccination is detailed in Supplementary Figure S1 [12]. In this model, the infection rate is estimated as the number of cases occurring per month in the entire susceptible population. The difference between the number of events expected in the absence of vaccination and the actual number observed was calculated to derive the burden averted by influenza vaccination [12].

We utilized the best-performing compartmental model (Primary Model) validated by Tokars et al. [12]. In this model, all population members start each season as susceptible (non-vaccinated and non-cases) and move through six compartments on a monthly timescale based on whether they are: ill or well; vaccinated or unvaccinated; and immune or susceptible. Proportions infected and vaccinated are calculated by applying current-month case and vaccination counts to prior-month compartment values, with no immune lag or indirect protection assumed. Infected persons are assumed to become immune to further infection, whereas vaccinated persons may develop complete immunity or remain fully susceptible. Vaccinations are assumed to be given with equal frequency to previously infected and uninfected individuals; however, this does not affect the immunity of previously

infected cases, who are assumed to have already attained complete immunity [12].

Modelled scenarios

In our base case scenario, central estimates of VE and coverage were used. The high scenario was generated using the upper 95% confidence limits for VE and coverage, and the low scenario was generated using the lower 95% confidence limits. Additionally, a hybrid scenario was run with varying VE and coverage across age groups to approximate variations observed in national and more recent datasets [11, 21, 22, 26]. The hybrid scenario assumed vaccination coverage was at the central estimate for the 0.5–4 year and 50–64 year age groups, the low estimate for the 5–14 year and 15–49 year age groups, and the high estimate for the ≥65 year age group. It also assumed the low VE estimate for the ≥65 year age group and the central estimate for all other age groups, as lower VE is often observed in those aged ≥65 years [11, 21]. Results were reported as absolute numbers, rates per 100000 population, and the prevented fraction of observed events [2].

Sensitivity analyses

A sensitivity analysis was performed, limiting influenza-related cases to those where selected diagnostic codes only appeared as the principal diagnosis. Additional analysis was also performed for influenza-specific hospitalizations (J09-J11) using the version of the compartmental model (Alternative Model) that was utilized prior to the update performed by Tokars et al. (Supplementary Table S1) [12]. This method incorporates a 14-day immune lag by averaging vaccination coverage across the current and prior month and applies coverage and VE to all susceptible persons (not infected or effectively vaccinated).

Economic analysis

We estimated the costs associated with observed influenza-related hospitalizations and ED attendances in Victoria, as well as the savings associated with the burden averted by vaccination. To do this, we conducted an economic analysis using a simplified model of the Australian national efficient cost determination, as set by the Independent Hospital and Aged Care Pricing Authority (IHACPA) [27]. This was conducted for the scenarios yielding the most credible results, based on comparison to previous studies – influenza-specific (J09-J11) hospitalizations and P&I (J09-J18) ED attendances.

Australian Refined Diagnosis Related Group (AR-DRG) version 8.0 codes were available in the VAED for all study years and were used to identify price weights for each hospitalization [27–29]. For hospitalizations, these were adjusted to account for length of stay, hours spent in an intensive care unit (ICU) for AR-DRG codes where ICU admission was not bundled, paediatric admissions, patient residential remoteness status, and Indigenous status [27]. Adjusted price weights for each event were used to generate an average price weight per hospitalization across the study period, which was then applied to the national efficient price of an acute care episode per calendar year to determine the average cost per influenza-related hospitalization for each year of the study [27–29]. This was then multiplied by the number of observed hospitalizations to estimate the costs of hospitalizations and by estimates of averted hospitalizations to calculate savings. All hospitalizations were analyzed according to public hospital costings. All results were adjusted to 2022 Australian Dollars, accounting for inflation [30].

The same method was used for ED attendance with more limited price weight adjustments, in line with the national efficient cost determination. Adjustments for ED attendance were for patient residential status, Indigenous status, and advanced age [27].

The estimated total costs of observed events and savings of averted events were reported for each year of the study period. Information regarding total costs of delivering influenza vaccination programmes in Victoria was not available for comparison because costs are spread across the state and federal governments as well as multiple private entities.

Ethical statement

Ethical approval for data access, analysis, and result distribution was provided by the Victorian Government Department of Health and Department of Families, Fairness and Housing Human Research Ethics Committee, reference 80628, and the Australian National University Human Research Ethics Committee, reference 2022/213.

Results

Observed hospitalizations and ED attendances

From 2017 to 2019, there were 22972 hospitalizations and 16168 ED attendances with influenza-specific diagnoses and 135182 hospitalizations and 61681 ED attendances with P&I diagnoses (Table 2). The number of events was highest in 2019, followed by 2017, with 2018 having substantially lower numbers. In total, 95% of hospitalizations in the P&I scenario and 96% of hospitalizations in the influenza-specific scenario were classified as emergency

admissions. The care type of remaining hospitalizations is summarized in Supplementary Table S2.

For hospitalizations in the influenza-specific scenario, 72.6% had a J09-J11 diagnosis recorded in the principal diagnostic field, with an additional 16.1% in the second, 4.2% in the third, and <2% in subsequent fields. For hospitalizations in the P&I scenario, 59.9% had a J09-J18 diagnosis recorded in the principal field, with an additional 15.8% in the second, 5.9% in the third, 3.0% in the fourth, 2.9% in the fifth, 2.4% in the sixth, and <2% in all subsequent fields (Supplementary Table S3).

For ED attendances in the influenza-specific scenario, 96.1% had a J09-J11 diagnosis recorded in the principal diagnostic field, with an additional 3.7% in the second and 0.2% in the third. For ED attendances in the P&I scenario, 96.4% had a J09-J18 diagnosis recorded in the principal diagnostic field, with an additional 3.3% in the second and 0.3% in the third (Supplementary Table S3).

The highest rates of hospitalizations in each year studied occurred in the ≥65 year age group across all scenarios. This was followed by the 50 – 64 year and 0.5 – 4 year age groups for influenza-specific and P&I hospitalizations and P&I ED attendances (Table 3). For ED attendances in the influenza-specific scenario, observed rates were more evenly distributed among those aged <65 years.

Hospitalizations and ED attendances averted by influenza vaccination

Influenza vaccination averted hospitalizations and ED attendances across all estimates in all years, except for the low scenario estimates in 2017, where VE was 0%, compared to 15% in the base scenario. Influenza vaccination reduced influenza-related events at the peak

Table 2. Total influenza-related hospitalizations and ED attendances averted by influenza vaccination reported by year, selected scenarios, Victoria, 2017 – 2019

		Hospitalizations										
Case definitions	Year	Observed		Averted base scenario			Averted low scenario			Averted high scenario		
		<i>n</i>	rate ^a	<i>n</i>	rate	pf ^b	<i>n</i>	rate	pf	<i>n</i>	rate	pf
Influenza-specific ^c	2017	8826	141	497	8	5	0	0	0	1660	27	16
	2018	3236	51	795	12	20	329	5	9	1656	26	34
	2019	10910	168	2254	35	17	1340	21	11	3515	54	24
P&I ^d	2017	45598	728	1974	32	4	0	0	0	6547	105	13
	2018	40054	628	8147	128	17	3517	55	8	16577	260	29
	2019	49530	763	10435	161	17	5976	92	11	16699	257	25
		Emergency department attendance										
Case definitions	Year	Observed		Averted base scenario			Averted low scenario			Averted high scenario		
		<i>n</i>	rate	<i>n</i>	rate	pf	<i>n</i>	rate	pf	<i>n</i>	rate	pf
Influenza-specific ^c	2017	5314	85	292	5	3	0	0	0	973	16	10
	2018	2287	36	536	8	14	227	4	7	1107	17	25
	2019	8567	132	1848	28	14	1106	17	9	2878	44	21
P&I ^d	2017	20082	321	918	15	2	0	0	0	3042	49	6
	2018	16291	255	3375	53	8	1456	23	4	6859	108	15
	2019	25308	390	5566	86	10	3207	49	6	8869	137	15

^aRate per 100000 population.

^bPf – prevented fraction = (events averted / (events averted + events)) * 100.

^cInfluenza-specific denotes events with an ICD-10-AM J09-J11 code in any diagnostic field.

^dP&I denotes pneumonia and influenza events with an ICD-10-AM J09-J18 code in any diagnostic field.

Table 3. Annual average influenza-related hospitalizations and ED attendances averted by influenza vaccination by age group, Victoria, 2017 – 2019

Case definition	Age group years	Hospitalizations									
		Observed		Averted base scenario		Averted low scenario		Averted high scenario		Averted hybrid scenario ^a	
		<i>n</i>	rate ^b	<i>n</i>	rate	<i>n</i>	rate	<i>n</i>	rate	<i>n</i>	rate
Influenza-specific ^c	0.5 – 4	435	98	74	17	36	8	136	31	74	17
	5 – 14	346	45	59	8	30	4	108	14	41	5
	15 – 49	1929	61	313	10	152	5	593	19	215	7
	50 – 64	1195	110	178	16	82	8	348	32	178	16
	65+	3752	407	558	61	256	28	1092	119	485	53
	All ages	7657	120	1182	19	556	9	2277	36	993	16
P&I ^d	0.5 – 4	2340	525	382	86	183	41	721	162	382	86
	5 – 14	952	124	153	20	74	10	290	38	101	13
	15 – 49	6147	195	955	30	449	14	1827	58	626	20
	50 – 64	6351	583	960	88	442	41	1865	171	960	88
	65+	29270	3179	4402	478	2017	219	8571	931	4289	466
	All ages	45061	707	6852	107	3164	50	13274	208	6358	100
Case definition	Age group years	Emergency department attendances									
		Observed		Averted base scenario		Averted low scenario		Averted high scenario		Averted hybrid scenario ^a	
		<i>n</i>	rate	<i>n</i>	rate	<i>n</i>	rate	<i>n</i>	rate	<i>n</i>	rate
Influenza-specific ^c	0.5 – 4	389	87	71	16	38	8	124	28	71	16
	5 – 14	480	63	87	11	46	6	153	20	62	8
	15 – 49	2518	80	418	13	208	7	774	25	289	9
	50 – 64	813	75	125	12	60	6	240	22	125	12
	65+	1189	129	191	21	93	10	361	39	174	19
	All ages	5389	85	892	14	444	7	1653	26	721	11
P&I ^d	0.5 – 4	1641	368	286	64	140	31	531	119	286	64
	5 – 14	1160	152	204	27	102	13	375	49	138	18
	15 – 49	5107	162	832	26	400	13	1566	50	556	18
	50 – 64	3144	289	495	45	231	21	951	87	495	45
	65+	9508	1033	1470	160	682	74	2833	308	1432	156
	All ages	20560	322	3286	52	1554	24	6257	98	2907	46

^aHybrid scenario assumptions: vaccination coverage – central estimate used for 0.5–4 year and 50–64 year age groups, low estimate for 5–14 year and 15–49 year age groups, and high estimate for 65+ year age group; vaccination effectiveness – low estimate for 65+ year age group and central estimate for all others.

^bRate per 100000 population.

^cInfluenza-specific denotes events with an ICD-10-AM J09-J11 code in any diagnostic field.

^dP&I denotes pneumonia and influenza events with an ICD-10-AM J09-J18 code in any diagnostic field.

of the influenza season (Figure 1). The rate of averted events was influenced by the baseline number and timing of observed events relative to vaccination, level of coverage and VE for each year. Although there was a high number of hospitalizations in 2017, VE was significantly lower than other years at 15% (95% CI, 0%–32%), and early season coverage was also relatively low. Of the three study years, 2019 had the highest rate of baseline events, highest vaccination coverage, and moderate VE at 43% (95% CI, 36%–49%). Comparatively, 2018 was the year with the lowest number of baseline events but the highest VE at 56% (95% CI, 44%–65%) and mid-ranking coverage (Table 1).

Accordingly, for the influenza-specific scenario, 2019 had the highest rate of hospitalizations and ED attendances averted, at

35 [range: 21–54] and 28 [17–44] per 100000 population, respectively (Table 2). Base and low scenario estimates of averted hospitalizations were higher in 2018 compared to 2017, at 12 [5–26] and 8 [0–27], respectively, with similar estimates in the high scenarios across both years. This was also true for rates of averted ED attendances, which were 8 [4–17] in 2018 and 5 [0–16] in 2017, respectively.

In the P&I scenario, the highest rate of averted events occurred in 2019 and the lowest in 2017, for hospitalizations, 161 [range: 92–257] and 32 [0–105], and ED attendance, 86 [range: 49–137] and 15 [0–49], respectively. The prevented fraction of events was approximately equal in 2018 and 2019 for hospitalizations at 17% [range: 8%–29%] in 2018 and 17% [11%–25%] in 2019, and also for ED attendance at 8% [4%–15%] in 2018 and 10% [6%–15%] in 2019.




Figure 1. Observed influenza-related hospitalizations and ED attendances vs modelled events in the absence of influenza vaccination, Victoria, 1 January 2017 to 31 December 2019. Influenza-specific hospitalizations defined as events with a J09-J11 ICD-10-AM code in any diagnostic field. P&I ED attendances defined as events with a J09-J18 ICD-10-AM code in any diagnostic field. Points indicate the central estimate, linked by lines to show the epidemic curve of influenza-related events. Shaded regions indicate the level of uncertainty around each central estimate (range). Data sources: VAED (hospitalizations) and VEMD (ED attendances).

In all scenarios, the highest rate of hospitalizations and ED attendances averted occurred in the ≥ 65 year age group (Table 3). This was followed by the 6 month to 4 year and 50 – 64 year age groups for hospitalizations (influenza-specific and P&I) and P&I ED attendance. The rate of influenza-specific ED attendance averted was comparatively similar among age groups < 65 years.

In the hybrid influenza-specific and P&I scenarios (Table 3, Supplementary Table S4), the number of events averted in the

≥ 65 year age group was predictably lower in 2017 (which had 0% VE) compared to the baseline scenario, but higher in 2018 and 2019, where lower VE was offset by higher coverage. The overall rates of hospitalizations and ED attendance averted in the hybrid scenario were marginally lower across the three-year study period compared to the primary analysis.

The burden and burden averted by age group for each year are presented in Supplementary Tables S5 and S6. Rates of

Table 4. Estimated costs of observed influenza-related hospitalizations and ED attendances and savings related to hospitalizations and ED attendances averted by influenza vaccination, Victoria, 2017 – 2019

Influenza-related (influenza-specific, J09-J11) hospitalizations										
Year	NEP ^a	Average cost per event	Observed events (n)	Costs observed events	Events averted (n)			Expenditure averted		
					Base scenario	Low scenario	High scenario	Base scenario	Low scenario	High scenario
2017	\$5622	\$8155	8826	\$71973975	497	0	1660	\$4052919	\$0	\$13536914
2018	\$5631	\$8168	3236	\$26431071	795	329	1656	\$6493418	\$2687213	\$13525913
2019	\$5677	\$8235	10910	\$89838889	2254	1340	3515	\$18560665	\$11034291	\$28944427
Total				\$188243936	Total			\$29107003	\$13721504	\$56007253
Average				\$62747979	Average			\$9702334	\$4573835	\$18669084
Influenza-related (pneumonia and influenza, J09-J18) emergency department attendances										
Year	NEP ^a	Average cost per event	Observed events (n)	Costs observed events	Events averted (n)			Expenditure averted		
					Base scenario	Low scenario	High scenario	Base scenario	Low scenario	High scenario
2017	\$5622	\$1081	20082	\$21712974	918	0	3042	\$992556	\$0	\$3289058
2018	\$5631	\$1083	16291	\$17642283	3375	1456	6859	\$3654945	\$1576770	\$7427931
2019	\$5677	\$1092	25308	\$27631104	5566	3207	8869	\$6076921	\$3501381	\$9683114
Total				\$66986361	Total			\$10724422	\$5078151	\$20400103
Average				\$22328787	Average			\$3574807	\$1692717	\$6800034
Combined hospitalizations and emergency department attendances										
Total				\$255230297	Total			\$39831425	\$18799655	\$76407357
Average				\$85076766	Average			\$13277142	\$6266552	\$25469119

Notes: Average price weighting calculated as 1.45051 for hospitalizations and 0.1923187 for ED attendances. Average savings per event is given by the National Efficient Price multiplied by the average price weighting. All figures reported in 2022 Australian Dollars [29], rounded to the nearest dollar.

^aNational Efficient Price.

Data Source: Independent Hospital Pricing Authority [26–28].

hospitalizations were lower in sensitivity analysis scenarios with cases defined by principal diagnosis only (Supplementary Table S7). Results for the Alternative Model were minimally different to the Primary Model (Supplementary Table S8).

Economic analysis

The modelled costs of influenza-specific hospitalizations equated to an annual average of A\$62748000 or A\$18824400 over the study period. The modelled costs of P&I ED attendances equated to an annual average of A\$22329000 or A\$66986000 over the study period (Table 4).

The modelled savings of influenza-specific averted hospitalizations were A\$29107000 over the study period [range: A\$13722000 – A\$56007000] (Table 4). The modelled savings for averted P&I ED attendance were estimated to be A\$10724000 [range: A\$5078000 – A\$20400000] over the study period.

Discussion

Observed hospitalizations and emergency department attendances

This study produced estimates of the baseline burden of influenza-related hospitalizations and ED attendances in Victoria, Australia, and calculated the burden averted by influenza vaccination. The scenario based on an influenza-specific diagnosis in any field most

closely aligned with the estimated burden of influenza-related hospitalizations in key studies from Australia [3, 32]. Influenza-related morbidity fluctuates yearly, such that comparisons within the same year are most relevant [2, 4, 6]. Nazareno et al. estimated 171 (95% CI, 147 – 190) influenza-related respiratory hospitalizations per 100000 population in 2017 in Australia using a multiple linear time series regression model [3]. Moa et al. determined through a semi-parametric generalized-additive model that the rate of respiratory hospitalizations attributable to influenza was 139 (95% CI, 130 – 149) per 100000 in the 50 – 64 year age group and 638 (95% CI, 609 – 667) per 100000 in the ≥65 year age group in Australia in 2017 [32]. In 2017, we calculated the baseline rate of influenza-specific hospitalizations to be 141 per 100000 for all age groups, 123 per 100000 in the 50 – 64 year age group, and 551 per 100000 in the ≥65 year age group (Supplementary Table S5). These results are comparable but suggest our results underestimate influenza-related hospitalizations, compared to studies using modelling techniques that facilitate the use of a broader range of ICD-10-AM codes to identify baseline rates of influenza-related events. This finding is consistent with data linkage studies that have concluded influenza-specific diagnostic codes do not identify all hospitalizations of individuals with a laboratory confirmed influenza diagnosis [20, 33].

For ED attendance, the P&I scenario yielded results that were the most comparable to previous studies, although direct comparisons within influenza seasons were not available. Muscatello et al. estimated that from 2010 to 2014, the rate of all-cause influenza-related presentations to NSW EDs was 309 (99.9% CI, 208 – 410),

using a time series regression analysis [6]. The observed baseline rate of P&I ED attendances in our study was 322 per 100000 population. The marginally higher estimate in our study is not unexpected, as we evaluated two seasons (2017 and 2019) with high influenza burden [11, 22]. There has also been an observed trend in Australia towards increased influenza-related presentations to EDs, accompanied by decreased hospitalization rates [4, 34]. Compared with international studies, our estimates remained lower than ED attendance rates for influenza-related illness in the United States (486 per 100000 from 2016 to 2018) [35] and Canada (500 per 100000 from 2003 to 2009, excluding the 2009 influenza A (H1N1) pandemic) [14].

Observed ED attendance rates in our study were substantially lower in the influenza-specific scenario, at only 85 per 100000 population. These results likely reflect a tendency to use more general diagnostic codes in the ED setting, where patients typically spend a brief period of time before being admitted or discharged, with influenza testing often pending at the time of departure or not performed [4, 34]. The P&I scenario appears to be a better approximation of influenza-related ED attendance. However, further research is needed to validate the use of ICD-10-AM codes in this setting.

Hospitalizations and ED attendance averted by influenza vaccination

Under the selected scenarios (J09-J11 for hospitalizations and J09-J18 for ED attendances), we estimated that influenza vaccination averted an annual average of 1182 [range: 556 – 2277] hospitalizations and 3286 [1554 – 6257] ED attendances in Victoria. Vaccination also resulted in reduced hospitalizations and ED attendances at the peak of each influenza season, which is especially important for mitigating health service demand [36]. Benefits were generally greatest in the ≥ 65 year age group, where individuals face the greatest risk of severe illness following influenza infection [3].

Only in 2017, in the low scenario with 0% VE, were there no apparent benefits to vaccination. This highlights the challenge of optimizing antigenic matching between vaccine viruses and viruses circulating in the community in the setting of continual antigenic drift and shifting subtype predominance. It also highlights the potential benefits of developing technologies to boost VE [7]. Although difficult to compare seasons, the decision to fund free high-dose and adjuvanted vaccines for adults aged ≥ 65 years after the 2017 season [9], may have contributed to the higher VE seen in 2018 and 2019 [37]. Ongoing efforts to improve VE and coverage have the potential to increase the benefits of influenza vaccination [38].

Economic analysis

Our estimate of A\$13 [range: A\$6 – A\$25] million per year includes savings to the hospital system in Victoria and does not account for savings associated with prevented general practice consultations, lost days of work, or premature deaths. As with our calculations of hospitalizations and ED attendance averted, this is likely to be an underestimate of hospital savings due to low estimates of averted events. We calculated the total costs of influenza-related hospitalizations to be A\$63 million per year in Victoria from 2017 to 2019. In comparison, Newall *et al.* calculated annual average influenza-related hospitalization costs in Australia to be A\$160 million over the period from 1998 to 2005 [5] (adjusted from 2005 to 2022 A\$ accounting for inflation) [29], with Victoria making up one quarter

of Australia's population between 1998 and 2019 [39]. The proportionately higher cost estimate in our study reflects a greater number and rate of hospitalizations (120 vs 106 per 100000 population), as Newall *et al.* utilized marginally higher cost estimates per hospitalization, which were also based on standardized national pricing [5]. Population growth, seasonal variability, an increasing proportion of the population aged ≥ 75 years, and a trend towards higher hospitalization rates with shorter lengths of stay may all account for the higher rates of hospitalizations observed in our study, in addition to methodological differences [40]. Newall *et al.* also estimated the annual average costs of general practice consults for influenza-related illness to be A\$16 million [5], accounting for inflation [30]. Extrapolating their finding of 10% of hospital costs to our study would imply A\$6.3 million in costs associated with influenza-related general practice visits per year in Victoria from 2017 to 2019. Improving VE and coverage would result in further cost reductions, as well as population health benefits [7].

Limitations

There is inherent uncertainty in the approach used in this study, which aims to quantify influenza burden in the hypothetical scenario of no vaccination [12]. Specific limitations include uncertainty around the accuracy of ICD-10-AM codes, as well as estimates of VE and coverage. Inaccuracies in any of these parameters could result in over- or underestimation of the burden of hospitalizations and ED attendances averted. There is considerable uncertainty around the accuracy of ICD-10-AM codes to estimate the number of influenza-related ED attendances. Although the P&I scenario produces more realistic estimates than the influenza-specific scenario, these should be considered a proxy measure, as there are both underestimation of the number of influenza cases and inclusion of some pneumonia cases related to alternative pathogens.

To mitigate uncertainty in VE and coverage estimates, we have incorporated scenarios utilizing 95% confidence limits for these parameters. We utilized VE estimates from the FluCAN network, which estimates VE against hospitalization with laboratory confirmed influenza, as the most comparable VE estimate available. Similar to our study, this estimate is concerned with VE in patients attending hospitals. However, unlike our study, these VE estimates utilize a case definition based on patients admitted to the hospital with a respiratory illness that has been laboratory-confirmed to be influenza rather than specified ICD-10-AM codes. VE estimates may also be less accurate for ED attendances in our study, as these cases did not necessarily proceed to admission. Differences in the outcomes used for VE calculation may lead to over- or underestimation of the estimated burden averted. VE can vary within an influenza season. However, as VE estimates used are averages generated across the duration of each year's influenza season, they approximate the average protection conferred by vaccination [41–43].

Sample sizes were insufficient to estimate vaccination coverage by month within each age group. We have accounted for potential variation in VE and coverage across age groups by incorporating a hybrid scenario, which used national and more recent estimates, to approximate and assess the impact of such variations. Following changes to legislation, influenza vaccinations administered in Australia have been required to be mandatorily reported to the Australian Immunisation Register since March 2021. Estimates for population coverage since this date are available from national data and no longer need to rely on sentinel surveillance platforms [44].

We have not accounted for the indirect benefits of vaccination or assessed the burden of non-respiratory influenza-related events

in instances where an influenza diagnostic code was not also recorded. This is likely to result in underestimation of the burden averted by influenza vaccination. We have also not assessed the effects of prior immunity from vaccination or infection, as Tokars et al. did not find this significantly affected results [12].

Conclusions

Our study has demonstrated that calculating the number of influenza-related hospitalizations and ED attendances averted by vaccination is feasible in Victoria and, by extension, Australia. The selection of ICD-10-AM codes and the definition of influenza-related events influence the calculated burden and may introduce greater uncertainty for ED attendances, where there are fewer established estimates for comparison. Influenza vaccination results in important reductions in hospital utilization and expenditure, including at the peak of the influenza season.

Supplementary material. The supplementary material for this article can be found at <http://doi.org/10.1017/S0950268824001122>.

Data availability statement. Data related to this study are available in the Supplementary Material or via publicly available resources, as listed. The R package used to run the compartmental model is available from Github [31]. Further information can be requested from the corresponding author.

Acknowledgements. The authors would like to acknowledge the Victorian Department of Health as the source of VAED and VEMD for this study.

Author contribution. Conceptualization: S.G.S.; Methodology: S.G.S., S.N., A.K., C.G.A.P.; Supervision: S.G.S., J.S., M.R.R.; Writing – review & editing: S.G.S., J.S., S.N., A.K., M.R.R., C.G.A.P.; Data curation: J.S., C.G.A.P.; Validation: S.N., A.K.; Visualization: A.K., C.G.A.P.; Formal analysis: C.G.A.P.; Investigation: C.G.A.P.; Writing – original draft: C.G.A.P.

Funding statement. The WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Aged Care. No specific funding was received for this work.

Competing interest. C.G.A.P., A.K., S.N., M.R.R., and J.S. – nothing to declare. S.G.S. has received honoraria from CSL Seqirus, Moderna, Pfizer, and Evo Health. The WHO Collaborating Centre for Reference and Research on Influenza has a collaborative research and development agreement (CRADA) with CSL Seqirus for isolation of candidate vaccine viruses in cells and an agreement with IFPMA for isolation of candidate vaccine viruses in eggs.

References

- [1] Federici C, Cavazza M, Costa F and Jommi C (2018) Health care costs of influenza-related episodes in high income countries: A systematic review. *PLoS One* **13**, e0202787. <https://doi.org/10.1371/journal.pone.0202787>.
- [2] Machado A, Mazagatos C, Dijkstra F, Kislaya I, Gherasim A, McDonald SA, Kissling E, Valenciano M, Meijer A, Hooiveld M, Nunes B, Larrauri A. (2019) Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons. *Euro Surveillance* **24**(45), 1900268. <https://doi.org/10.2807/1560-7917.Es.2019.24.45.1900268>.
- [3] Nazareno AL, Muscatello DJ, Turner RM, Wood JG, Moore HC and Newall AT (2022) Modelled estimates of hospitalisations attributable to respiratory syncytial virus and influenza in Australia, 2009–2017. *Influenza and Other Respiratory Viruses* **16**, 1082–1090. <https://doi.org/10.1111/irv.13003>.
- [4] Boyle J, Crilly J, Keijzers G, Wallis M, Lind J, Sparks R, et al. (2012) Impact of influenza across 27 public emergency departments in Australia: A 5-year descriptive study. *Emergency Medicine Journal* **29**, 725–731. <https://doi.org/10.1136/emmermed-2011-200230>.
- [5] Newall AT and Scuffham PA (2008) Influenza-related disease: the cost to the Australian healthcare system. *Vaccine* **26**, 6818–6823. <https://doi.org/10.1016/j.vaccine.2008.09.086>.
- [6] Muscatello DJ, Bein KJ and Dinh MM (2017) Emergency department demand associated with seasonal influenza, 2010 through 2014, New South Wales, Australia. *Western Pacific Surveillance and Response Journal* **8**, 11–20. <https://doi.org/10.5365/wpsar.2017.8.2.002>.
- [7] Jamotte A, Chong CF, Manton A, Macabeo B and Toumi M (2016) Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia. *BMC Public Health* **16**, 630. <https://doi.org/10.1186/s12889-016-3297-1>.
- [8] Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, et al. (2013) Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005–2011. *PLoS One* **8**, e66312. <https://doi.org/10.1371/journal.pone.0066312>.
- [9] Victorian Government Department of Health (2023) Vaccine History Timeline Melbourne: Victorian Government Department of Health; [updated 2023 June 6; cited 2023 June 6]. Available at <https://www.health.vic.gov.au/immunisation/vaccine-history-timeline>.
- [10] Victorian Government Department of Health (2023) Better Health Channel: Influenza (flu) - immunisation Melbourne: Victorian Government Department of Health; [updated 2023 March 3; cited 2023 November 2]. Available at <https://www.betterhealth.vic.gov.au/health/healthyliving/flu-influenza-immunisation>.
- [11] Cheng AC, Holmes M, Dwyer DE, Senanayake S, Cooley L, Irving LB, et al. (2019) Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN). *Communicable Diseases Intelligence* (2018) **43**. <https://doi.org/10.33321/cdi.2019.43.39>.
- [12] Tokars JI, Rolfes MA, Foppa IM and Reed C (2018) An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. *Vaccine* **36**, 7331–7337. <https://doi.org/10.1016/j.vaccine.2018.10.026>.
- [13] Chung JR, Rolfes MA, Flannery B, Prasad P, O'Halloran A, Garg S, et al. (2020) Effects of influenza vaccination in the United States during the 2018–2019 influenza season. *Clinical Infectious Diseases* **71**, e368–e376. <https://doi.org/10.1093/cid/ciz1244>.
- [14] Schanzer DL and Schwartz B (2013) Impact of seasonal and pandemic influenza on emergency department visits, 2003–2010, Ontario, Canada. *Academic Emergency Medicine* **20**, 388–397. <https://doi.org/10.1111/acem.12111>.
- [15] Sullivan SG (2022) Preparing for out-of-season influenza epidemics when international travel resumes. *Medical Journal of Australia* **216**, 25–26. <https://doi.org/10.5694/mja2.51340>.
- [16] Australian Bureau of Statistics (2023) National, State and Territory Population Tables Canberra: Australian Bureau of Statistics; [updated 2022 September 14; cited 2023 March 17]. Available at <https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release#data-downloads-data-cubes>.
- [17] Victorian Government Department of Health (2021) *Victorian Admitted Episodes Dataset (VAED) Manual 2021–22*. Melbourne: Victorian Government Department of Health; [cited 2023 March 17]. Available at <https://www.health.vic.gov.au/publications/vaed-manual-2021-22-all-sections>.
- [18] Victorian Government Department of Health (2022) *Victorian Emergency Minimum Dataset (VEMD) Manual 2022–2023*. Melbourne: Victorian Government Department of Health; [cited 2023 March 17]. Available at <https://www.health.vic.gov.au/publications/victorian-emergency-minimum-dataset-vemd-manual-2022-2023>.
- [19] Australian Bureau of Statistics (2020) *Hospital Output Measures in the Australian National Accounts: Experimental Estimates, 2004–05 to 2017–18*. Canberra: Australian Bureau of Statistics [updated September 28; cited 2023 November 26]. Available at <https://www.abs.gov.au/statistics/research/hospital-output-measures-australian-national-accounts-experimental-estimates-2004-05-2017-18#overview-of-hospital-services>.
- [20] Wabe N, Li L, Lindeman R, Post JJ, Dahm MR, Li J, et al. (2021) Evaluation of the accuracy of diagnostic coding for influenza compared to laboratory results: the availability of test results before hospital

- discharge facilitates improved coding accuracy. *BioMed Central Medical Informatics and Decision Making* **21**, 168. <https://doi.org/10.1186/s12911-021-01531-9>.
- [21] **Cheng AC, Holmes M, Dwyer DE, Senanayake S, Cooley L, Irving LB, et al.** (2019) Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN). *Communicable Diseases Intelligence* (2018) **43**. <https://doi.org/10.33321/cdi.2019.43.48>.
- [22] **Cheng AC, Dwyer DE, Holmes M, Irving L, Simpson G, Senanayake S, et al.** (2022) Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2019: the Influenza Complications Alert Network (FluCAN). *Communicable Diseases Intelligence* (2018) **46**. <https://doi.org/10.33321/cdi.2022.46.14>.
- [23] **Kelly PM, Kotsimbos T, Reynolds A, Wood-Baker R, Hancox B, Brown SG, et al.** (2011) FluCAN 2009: initial results from sentinel surveillance for adult influenza and pneumonia in eight Australian hospitals. *The Medical Journal of Australia* **194**(4), 169–174. <https://doi.org/10.5694/j.1326-5377.2011.tb03764.x>.
- [24] **Bodner K, Irvine MA, Kwong JC and Mishra S** (2023) Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies. *International Journal Infectious Diseases* **131**, 111–114. <https://doi.org/10.1016/j.ijid.2023.03.022>.
- [25] **Price OH, Carville KS and Sullivan SG** (2019) Right sizing for vaccine effectiveness studies: how many is enough for reliable estimation? *Communicable Diseases Intelligence* (2018) **43**. <https://doi.org/10.33321/cdi.2019.43.20>.
- [26] **National Centre for Immunisation Research and Surveillance Australia** (2023) Influenza Vaccine Coverage Data Westmead: National Centre for Immunisation Research and Surveillance Australia [updated 2023 April 2; cited 2023 September 7]. Available at <https://ncirs.org.au/influenza-vaccination-coverage-data>.
- [27] **Independent Hospital Pricing Authority** (2019) *National Efficient Price Determination 2019-20*. Sydney: Independent Hospital Pricing Authority; [cited 2023 March 17]. Available at <https://www.ihacpa.gov.au/resources/national-efficient-price-determination-2019-20>.
- [28] **Independent Hospital Pricing Authority** (2017) *National Efficient Price Determination 2017-18*. Sydney: Independent Hospital Pricing Authority; [cited 2023 March 17]. Available at <https://www.ihacpa.gov.au/resources/national-efficient-price-determination-2017-18>.
- [29] **Independent Hospital Pricing Authority** (2018) *National Efficient Price Determination 2018-19*. Sydney: Independent Hospital Pricing Authority; [cited 2023 March 17]. Available at <https://www.ihacpa.gov.au/resources/national-efficient-price-determination-2018-19>.
- [30] **Reserve Bank of Australia** (2023) Inflation Calculator Sydney: Reserve Bank of Australia; [updated 2022 January; cited 2023 March 29]. Available at <https://www.rba.gov.au/calculator/annualDecimal.html>.
- [31] **Kvorov A** (2020) Impactflu. Melbourne: Github [updated 2020 Jan 14; cited 2023 Nov 14]. Available at <https://github.com/cran/impactflu/tree/master>.
- [32] **Moa AM, Menzies RI, Yin JK and MacIntyre CR** (2022) Modelling the influenza disease burden in people aged 50-64 and ≥65 years in Australia. *Influenza and Other Respiratory Viruses* **16**, 132–141. <https://doi.org/10.1111/irv.12902>.
- [33] **Lim FJ, Blyth CC, Fathima P, de Klerk N and Moore HC** (2017) Record linkage study of the pathogen-specific burden of respiratory viruses in children. *Influenza and Other Respiratory Viruses* **11**, 502–510. <https://doi.org/10.1111/irv.12508>.
- [34] **Dinh MM, Berendsen Russell S, Bein KJ, Chalkley D, Muscatello D, Paoloni R, et al.** (2016) Understanding drivers of demand for emergency service trends in years 2010-2014 in New South Wales: an initial overview of the DESTINY project. *Emergency Medicine Australasia* **28**, 179–186. <https://doi.org/10.1111/1742-6723.12542>.
- [35] **Reid LD and Fingar KR** (2020) Emergency department visits involving influenza and influenza-like illnesses, 2016–2018. In *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*. Rockville (MD): Agency for Healthcare Research and Quality (US).
- [36] **Sivey P, McAllister R, Vally H, Burgess A and Kelly AM** (2019) Anatomy of a demand shock: quantitative analysis of crowding in hospital emergency departments in Victoria, Australia during the 2009 influenza pandemic. *PLoS One* **14**, e0222851. <https://doi.org/10.1371/journal.pone.0222851>.
- [37] **Nguyen VH, Pugliese A, Ruiz-Aragón J, Uruña A, Mould-Quevedo J** (2023) Real-world evidence in cost-effectiveness analysis of enhanced influenza vaccines in adults ≥ 65 years of age: literature review and expert opinion. *Vaccines* **11**(6), 1089. <https://doi.org/10.3390/vaccines11061089>.
- [38] **Hughes MM, Reed C, Flannery B, Garg S, Singleton JA, Fry AM, et al.** (2020) Projected population benefit of increased effectiveness and coverage of influenza vaccination on influenza burden in the United States. *Clinical Infectious Diseases* **70**, 2496–2502. <https://doi.org/10.1093/cid/ciz676>.
- [39] **Australian Bureau of Statistics** (2023) Population clock and pyramid Canberra: Australian Bureau of Statistics; [updated 2023 October 21; cited 2023 October 21]. Available at <https://www.abs.gov.au/statistics/people/population/population-clock-pyramid>.
- [40] **Reid N, Gamage T, Duckett SJ and Gray LC** (2023) Hospital utilisation in Australia, 1993-2020, with a focus on use by people over 75 years of age: a review of AIHW data. *Medical Journal of Australia* **219**, 113–119. <https://doi.org/10.5694/mja2.52026>.
- [41] **Cheng AC, Holmes M, Dwyer DE, Senanayake S, Cooley L, Irving LB, Simpson G, Korman T, Macartney K, Friedman ND, Wark P, Howell A, Blyth CC, Crawford N, Buttery J, Bowler S, Upham JW, Waterer GW, Kotsimbos T, Kelly PM** (2019) Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN). *Commun Dis Intell* (2018) **43**. <https://doi.org/10.33321/cdi.2019.43.48>. Epub 18/11/2019.
- [42] **Cheng AC, Holmes M, Dwyer DE, Senanayake S, Cooley L, Irving LB, Simpson G, Korman T, Macartney K, Friedman ND, Wark P, Howell A, Blyth CC, Bowler S, Upham J, Waterer GW, Kotsimbos T, Kelly PM.** (2022) Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN). *Commun Dis Intell* (2018) **46**. <https://doi.org/10.33321/cdi.2022.46.14>.
- [43] **Cheng AC, Holmes M, Dwyer DE, Senanayake S, Cooley L, Irving LB, et al.** (2019) Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN). *Communicable Diseases Intelligence* (2018) **43**. <https://doi.org/10.33321/cdi.2019.43.39>.
- [44] Australian Immunisation Register Amendment (Reporting) Act 2021 (No. 1, 2021) - Schedule 1 (2021).